SEARCH RESULTS for NOVARTIS AG

Recent Patent Assignments Patent Assignments - (Total found: 195)

Last Update Patent(s) Assignor(s) Orig. Assignee(s) Assignee(s) Reel/Frame
18-Aug-2017

(X0) 15029363: CROSSLINKABLE POLYMER

(A1) 20160264701: CROSSLINKABLE POLYMER

ALCON JAPAN LTD.

NOVARTIS AG

43321/667

18-Aug-2017

(X0) 15029363: CROSSLINKABLE POLYMER

(A1) 20160264701: CROSSLINKABLE POLYMER

ALCON RESEARCH, LTD.

NOVARTIS AG

43321/696

18-Aug-2017

(X0) 15029363: CROSSLINKABLE POLYMER

(A1) 20160264701: CROSSLINKABLE POLYMER

CIBA VISION GMBH

NOVARTIS AG

43321/644

16-Aug-2017

(X0) 15005745: DELIVERY SYSTEM FOR OCULAR IMPLANT

(A1) 20160135992: DELIVERY SYSTEM FOR OCULAR IMPLANT

TRANSCEND MEDICAL, INC.

NOVARTIS AG

43296/270

11-Aug-2017

(X0) 15186025: COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES

(A1) 20160297854: COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES

NOVARTIS PHARMA AG

NOVARTIS AG

43263/211

11-Aug-2017

(X0) 15186025: COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES

(A1) 20160297854: COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

43262/263

28-Jul-2017

(X0) 15268305: OCULAR IMPLANT CONTAINER

(A1) 20170079839: OCULAR IMPLANT CONTAINER

TRANSCEND MEDICAL, INC.

NOVARTIS AG

43117/335

26-Jul-2017

(X0) 14364478: AEROSOLIZATION APPARATUS FOR INHALATION PROFILE-INDEPENDENT DRUG DELIVERY

(A1) 20140318539: AEROSOLIZATION APPARATUS FOR INHALATION PROFILE-INDEPENDENT DRUG DELIVERY

NOVARTIS PHARMACEUTICALS CORPORATION

NOVARTIS AG

43086/519

14-Jul-2017

(X0) 15403919: ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES

(A1) 20170137814: ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

42994/131

10-Jul-2017

(X0) 14777873: COMBINATION THERAPY

(A1) 20160296520: COMBINATION THERAPY

CAPONIGRO, GIORDANO

STUART, DARRIN

DE PARSEVAL, LAURE

NOVARTIS AG

42933/361

29-Jun-2017

(X0) 15460633: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

(A1) 20170183348: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

NOVARTIS PHARMA AG

NOVARTIS AG

42124/934

29-Jun-2017

(X0) 15460633: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

(A1) 20170183348: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

AURIGENE DISCOVERY TECHNOLOGIES LIMITED

NOVARTIS AG

42125/496

29-Jun-2017

(X0) 15231005: PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

(A1) 20170183352: PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

ASTEX THERAPEUTICS LIMITED

NOVARTIS AG

40346/967

29-Jun-2017

(X0) 15231005: PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

(A1) 20170183352: PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

40346/570

29-Jun-2017

(X0) 15460633: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

(A1) 20170183348: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

AURIGENE DISCOVERY TECHNOLOGIES LIMITED

NOVARTIS AG

42125/30

29-Jun-2017

(X0) 15348346: CURABLE COLORED INKS FOR MAKING COLORED SILICONE HYDROGEL LENSES

(A1) 20170183520: CURABLE COLORED INKS FOR MAKING COLORED SILICONE HYDROGEL LENSES

ALCON RESEARCH, LTD.

NOVARTIS AG

41105/158

29-Jun-2017

(X0) 15231005: PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

(A1) 20170183352: PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

BRAIN, CHRISTOPHER THOMAS

BROOKS, CLINTON A.

HE, GUO

HOU, YING

LU, YIPIN

SMITH, TROY

SUNG, MOO JE

WRONA, WOJCIECH

LI, YUE

NOVARTIS AG

40346/369

29-Jun-2017

(X0) 15300296: SYSTEM FOR DISINFECTING CONTACT LENSES

(A1) 20170182201: SYSTEM FOR DISINFECTING CONTACT LENSES

ALCON RESEARCH, LTD.

NOVARTIS AG

39959/154

29-Jun-2017

(X0) 15324468: IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2

(A1) 20170183403: IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2

NOVARTIS PHARMA AG

NOVARTIS AG

41776/895

29-Jun-2017

(X0) 15460633: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

(A1) 20170183348: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

NOVARTIS PHARMA AG

NOVARTIS AG

42125/319

29-Jun-2017

(X0) 15460633: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

(A1) 20170183348: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

42125/140

29-Jun-2017

(X0) 15460633: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

(A1) 20170183348: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

42124/831

19-Jun-2017

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

NOVARTIS AG

42730/740

19-Jun-2017

NOVARTIS PHARMA AG

NOVARTIS AG

42730/819

14-Jun-2017

(X0) 15149641: HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

(A1) 20160257656: HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

SPINIFEX PHARMACEUTICALS PTY LTD

NOVARTIS AG

42693/164

09-Jun-2017

(X0) 09939145: PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM

(A1) 20020086160: PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM

(B2) 6893685: PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM

QIU, YONGXING

WINTERTON, LYNN COOK

LALLY, JOHN MARTIN

PASIC, PAUL

GRIESSER, HANS

KAMBOURIS, PETER

CHABRECEK, PETER

N/A

42641/278

31-May-2017

(X0) 15303890: PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

(A1) 20170029414: PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

NOVARTIS PHARMACEUTICALS UK LTD

NOVARTIS AG

42525/772

31-May-2017

(X0) 15303868: AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

(A1) 20170042889: AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

NOVARTIS PHARMACEUTICALS UK LTD

NOVARTIS AG

42525/568

31-May-2017

(X0) 15303879: AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

(A1) 20170037032: AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

NOVARTIS PHARMACEUTICALS UK LTD

NOVARTIS AG

42525/626

12-May-2017

(X0) 15318191: SITE SPECIFIC PROTEIN MODIFICATIONS

(A1) 20170107248: SITE SPECIFIC PROTEIN MODIFICATIONS

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

42339/273

12-May-2017

(X0) 15312267: METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS

(A1) 20170095572: METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

42340/812

12-May-2017

(X0) 14680860: TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

(A1) 20150283178: TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

NOVARTIS AG

42347/411

12-May-2017

(X0) 14680860: TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

(A1) 20150283178: TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

NOVARTIS AG

42347/452

03-May-2017

(X0) 15166576: Organic Compositions to Treat Beta-ENaC-Related Diseases

(A1) 20160272979: Organic Compositions to Treat Beta-ENaC-Related Diseases

DIENER, JOHN L.

HICKMAN, EMMA

PULICHINO, ANNE-MARIE

NOVARTIS AG

42205/1

03-May-2017

(X0) 15166576: Organic Compositions to Treat Beta-ENaC-Related Diseases

(A1) 20160272979: Organic Compositions to Treat Beta-ENaC-Related Diseases

ALNYLAM PHARMACEUTICALS, INC.

NOVARTIS AG

42205/120

03-May-2017

(X0) 15135296: Novel Amino Pyrimidine Derivatives

(A1) 20160235746: Novel Amino Pyrimidine Derivatives

NOVARTIS PHARMA AG

NOVARTIS AG

42213/787

01-May-2017

(X0) 15073766: Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

(A1) 20160304489: Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD

NOVARTIS AG

42175/31

01-May-2017

(X0) 15073766: Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

(A1) 20160304489: Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

NOVARTIS PHARMA AG

NOVARTIS AG

42174/747

01-May-2017

(X0) 15073766: Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

(A1) 20160304489: Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

BEIJING NOVARTIS PHARMA CO. LTD.

NOVARTIS AG

42175/306

28-Apr-2017

8905930: INFUSION PRESSURE CONTROL USING BLOOD PRESSURE

9415162: INFUSION PRESSURE CONTROL USING BLOOD PRESSURE

ALCON RESEARCH LTD.

N/A

N/A

NOVARTIS AG

42137/145

26-Apr-2017

(X0) 10409926: PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM

(A1) 20040018295: PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM

(B2) 7040756: PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM

QUIU, YONGXING

WINTERTON, LYNN COOK

LALLY, JOHN MARTIN

N/A

NOVARTIS AG

42114/431

22-Apr-2017

(X0) 15051446: COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

(A1) 20160303129: COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

NOVARTIS INTERNATIONAL PHARMACEUTICAL AG

NOVARTIS AG

42093/410

20-Apr-2017

(X0) 15034280: COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS

(A1) 20160340317: COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS

NOVARTIS INTERNATIONAL PHARMACEUTICAL AG

NOVARTIS AG

42063/66

20-Apr-2017

(X0) 14886413: STEREO-OPTIC SURGICAL CONTACT LENS

(A1) 20170105620: STEREO-OPTIC SURGICAL CONTACT LENS

ALCON RESEARCH, LTD.

NOVARTIS AG

36841/987

20-Apr-2017

(X0) 15336555: SOFT TIP CANNULA

(A1) 20170106164: SOFT TIP CANNULA

ALCON RESEARCH, LTD.

NOVARTIS AG

40155/405

14-Apr-2017

(X0) 14533266: INFUSION PRESSURE CONTROL USING BLOOD PRESSURE

(A1) 20160000604: INFUSION PRESSURE CONTROL USING BLOOD PRESSURE

ALCON RESEARCH, LTD.

NOVARTIS AG

41996/455

14-Apr-2017

(X0) 14293613: INFUSION PRESSURE CONTROL USING BLOOD PRESSURE

(A1) 20140276558: INFUSION PRESSURE CONTROL USING BLOOD PRESSURE

ALCON RESEARCH, LTD.

NOVARTIS AG

41997/584

12-Apr-2017

(X0) 15110511: N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2

(A1) 20170015680: N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

NOVARTIS AG

41940/296

12-Apr-2017

(X0) 15110504: 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2

(A1) 20170001975: 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

NOVARTIS AG

41966/906

12-Apr-2017

(X0) 15008326: FEMTOSECOND ULTRAVIOLET LASER

(A1) 20160240996: FEMTOSECOND ULTRAVIOLET LASER

WAVELIGHT GMBH

NOVARTIS AG

41970/803